Higher county-level prostate cancer screening tied to better outcomes
Jun 07, 2024
nalysis included 814,987 men (aged 40 to 99 years) with prostate cancer followed up for up to 10 years through cancer registries in eight US states.
Adherence to Mediterranean diet linked to lower risk for mortality
Jun 04, 2024
Reduction in risk is partly explained by multiple cardiometabolic factors, including small molecule metabolites, inflammatory biomarkers
Excess mortality persisted in Western world from 2020 through 2022
Jun 04, 2024
Excess deaths continued in 2022, when most COVID-19 containment measures were lifted and COVID-19 vaccines were continued.
Expert panel develops new definition of long COVID
Jun 11, 2024
A new proposed definition for Long COVID could help patients get the help they need, a new report from the National Academies of Sciences, Engineering and Medicine says.
Odds of death lower with surgery for hip fracture in patients with dementia
Jun 03, 2024
A reduced odds of 180-day mortality was seen for patients with moderate to severe or mild dementia treated surgically.
FDA rescinds ban on Juul e-cigarettes
Jun 07, 2024
The agency said it needs to review both new court decisions and updated data from the vape maker. While the company’s e-cigarettes are back under review, they have not been fully cleared for sale...
Race-neutral metrics more accurately predict risk in COPD
May 31, 2024
The GLI-Global differentiated all-cause mortality risk between normal spirometry and first grade of COPD in adjusted analyses.
Semaglutide cuts risk for kidney outcomes, death in CKD with T2DM
May 31, 2024
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.
Virtual reality therapy can augment depression treatment
May 13, 2024
Extended reality-enhanced behavioral activation (XR-BA) may be a feasible enhancement to traditional BA for major depressive disorder.
Semaglutide boosts kidney outcomes with obesity + cardiovascular disease
May 28, 2024
At the prespecified 104-week time point, semaglutide was associated with a lesser decline in eGFR than placebo.